SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.13-0.5%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike Kapul who wrote (6338)5/21/1998 10:52:00 AM
From: aknahow  Read Replies (3) of 17367
 
Mike, thanks to you for the repost and also to the original poster.

For new readers and to prevent confusion there are some errors in the original posting of the numbers involved in the meningococemi trial. Presently accrual is above 200. Perhaps the 120 posted was meant to be 210. Likewise the 52 minimum figure is incorrect. Trial was expanded from I believe 130 to 200 or end of December 1998.

The importance of ORPHAN Drug status in a month or so should not be overlooked. I admit a bit of confusion not having been there and not having heard about such status from my only other source of information. I understood they were going to file in Europe either on the basis of existing data or on data available as soon as the trial ended. I do not know if that is what is now being referred to as ORPHAN drug filing. Does not seem like it. While such status would permit use of Neuprex only for meningococcemia it would, help some really sick kids, provide immediate marketing, and be worthy of a lot of good p.r. Then when trial is complete a full filing would be made.

Hope more information is provided by XOMA quickly as this seems to be very good news and yet the market does not yet reflect it. Or, the market does reflect this news and it is I who am failing to grasp the true meaning.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News